These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
171 related articles for article (PubMed ID: 8117420)
21. Hemicholinium-3 impairs spatial learning and the deficit is reversed by cholinomimetics. Hagan JJ; Jansen JH; Broekkamp CL Psychopharmacology (Berl); 1989; 98(3):347-56. PubMed ID: 2526345 [TBL] [Abstract][Full Text] [Related]
22. Enhanced performance of spatial and visual recognition memory tasks by the selective acetylcholinesterase inhibitor E2020 in rhesus monkeys. Rupniak NM; Tye SJ; Field MJ Psychopharmacology (Berl); 1997 Jun; 131(4):406-10. PubMed ID: 9226744 [TBL] [Abstract][Full Text] [Related]
23. Acetylcholinesterase inhibitors ameliorate behavioral deficits in the Tg2576 mouse model of Alzheimer's disease. Dong H; Csernansky CA; Martin MV; Bertchume A; Vallera D; Csernansky JG Psychopharmacology (Berl); 2005 Aug; 181(1):145-52. PubMed ID: 15778881 [TBL] [Abstract][Full Text] [Related]
24. The M1 Muscarinic Positive Allosteric Modulator PQCA Improves Performance on Translatable Tests of Memory and Attention in Rhesus Monkeys. Lange HS; Cannon CE; Drott JT; Kuduk SD; Uslaner JM J Pharmacol Exp Ther; 2015 Dec; 355(3):442-50. PubMed ID: 26446308 [TBL] [Abstract][Full Text] [Related]
25. Pharmacological studies on novel muscarinic agonists, 1-oxa-8-azaspiro[4.5]decane derivatives, YM796 and YM954. Wanibuchi F; Konishi T; Harada M; Terai M; Hidaka K; Tamura T; Tsukamoto S; Usuda S Eur J Pharmacol; 1990 Oct; 187(3):479-86. PubMed ID: 1963596 [TBL] [Abstract][Full Text] [Related]
26. The scopolamine-reversal paradigm in rats and monkeys: the importance of computer-assisted operant-conditioning memory tasks for screening drug candidates. Buccafusco JJ; Terry AV; Webster SJ; Martin D; Hohnadel EJ; Bouchard KA; Warner SE Psychopharmacology (Berl); 2008 Aug; 199(3):481-94. PubMed ID: 17657478 [TBL] [Abstract][Full Text] [Related]
27. Donepezil reverses a mnemonic deficit produced by scopolamine but not by perforant path lesion or transient cerebral ischaemia. Higgins GA; Enderlin M; Fimbel R; Haman M; Grottick AJ; Soriano M; Richards JG; Kemp JA; Gill R Eur J Neurosci; 2002 Jun; 15(11):1827-40. PubMed ID: 12081663 [TBL] [Abstract][Full Text] [Related]
28. Pharmacological characterization of the novel cholinomimetic L-689,660 at cloned and native brain muscarinic receptors. Aagaard P; McKinney M J Pharmacol Exp Ther; 1993 Dec; 267(3):1478-83. PubMed ID: 8263809 [TBL] [Abstract][Full Text] [Related]
29. Effects of the cholinesterase inhibitors donepezil and metrifonate on scopolamine-induced impairments in the spatial cone field orientation task in rats. van der Staay FJ; Bouger PC Behav Brain Res; 2005 Jan; 156(1):1-10. PubMed ID: 15474645 [TBL] [Abstract][Full Text] [Related]
30. Discriminative stimulus properties of the muscarinic receptor agonists Lu 26-046 and O-Me-THPO in rats: evidence for involvement of different muscarinic receptor subtypes. Arnt J; Lembøl HL; Meier E; Pedersen H Eur J Pharmacol; 1992 Jul; 218(1):159-69. PubMed ID: 1397027 [TBL] [Abstract][Full Text] [Related]
31. Donepezil primarily attenuates scopolamine-induced deficits in psychomotor function, with moderate effects on simple conditioning and attention, and small effects on working memory and spatial mapping. Lindner MD; Hogan JB; Hodges DB; Orie AF; Chen P; Corsa JA; Leet JE; Gillman KW; Rose GM; Jones KM; Gribkoff VK Psychopharmacology (Berl); 2006 Nov; 188(4):629-40. PubMed ID: 17004085 [TBL] [Abstract][Full Text] [Related]
32. Sabcomeline (SB-202026), a functionally selective M1 receptor partial agonist, reverses delay-induced deficits in the T-maze. Hatcher JP; Loudon JM; Hagan JJ; Clark MS Psychopharmacology (Berl); 1998 Aug; 138(3-4):275-82. PubMed ID: 9725749 [TBL] [Abstract][Full Text] [Related]
33. Comparative effects of the alpha7 nicotinic partial agonist, S 24795, and the cholinesterase inhibitor, donepezil, against aging-related deficits in declarative and working memory in mice. Marighetto A; Valerio S; Desmedt A; Philippin JN; Trocmé-Thibierge C; Morain P Psychopharmacology (Berl); 2008 Apr; 197(3):499-508. PubMed ID: 18265960 [TBL] [Abstract][Full Text] [Related]
34. Effects of the potassium channel blockers, apamin and 4-aminopyridine, on scopolamine-induced deficits in the delayed matching to position task in rats: a comparison with the cholinesterase inhibitor E2020. Poorheidari G; Stanhope KJ; Pratt JA Psychopharmacology (Berl); 1998 Feb; 135(3):242-55. PubMed ID: 9498727 [TBL] [Abstract][Full Text] [Related]
35. Effects of muscarinic receptor agonists and anticholinesterase drugs on high voltage spindles and slow waves. Riekkinen P; Riekkinen M; Fisher A; Ekonsalo T; Sirviö J Eur J Pharmacol; 1993 Aug; 240(1):1-7. PubMed ID: 8405117 [TBL] [Abstract][Full Text] [Related]
36. Effect of selective muscarinic receptor agonists and antagonists on active-avoidance learning acquisition in rats. Sen AP; Bhattacharya SK Indian J Exp Biol; 1991 Feb; 29(2):136-9. PubMed ID: 1869297 [TBL] [Abstract][Full Text] [Related]
37. Repeated inhibition of cholinesterase by chlorpyrifos in rats: behavioral, neurochemical and pharmacological indices of tolerance. Bushnell PJ; Kelly KL; Ward TR J Pharmacol Exp Ther; 1994 Jul; 270(1):15-25. PubMed ID: 7518512 [TBL] [Abstract][Full Text] [Related]
38. Comparative studies of huperzine A, E2020, and tacrine on behavior and cholinesterase activities. Cheng DH; Tang XC Pharmacol Biochem Behav; 1998 Jun; 60(2):377-86. PubMed ID: 9632220 [TBL] [Abstract][Full Text] [Related]